Compared to utilizing sulphonylureas, the results demonstrated that using DPP-4 inhibitors significantly lowers the incidence of hypoglycemia, with an odds ratio of 0.38 (95% confidence interval: 0.26 to 0.55, p value 0.00001). This evidence concerns the gene DPP4 and Hypoglycemia.